21.11.2018
DEINOVE confirms its financing options by renewing its equity line
The equity line funding set up in December 2014 expired. It has enabled DEINOVE to raise €9.4 million net in a flexible, optimized manner...
Press releases
27.09.2018
2018 half-year consolidated results: strengthened financial situation, substantial progress in both areas of business
Cash position: +€9.9m at June 30, 2018 compared to +€4.9m at December 31, 2017 thanks to the reinforcement of shareholders' equity Half-...
15.06.2018
DEINOVE: Successful capital increase of € 8.5 million
Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia and Japan. The...
23.05.2018
General meeting of May 23: Shareholders approve the acquisition of MORPHOCHEM
The General Meeting approved the contribution in kind of the BIOVERTIS (parent company of MORPHOCHEM) shares and options and the issuance...
13.04.2018
DEINOVE takes on a whole new dimension with the acquisition of MORPHOCHEM’s clinical-stage antibiotic compound
MORPHOCHEM's MCB3837 antibiotic compound aims to treat severe gastrointestinal infections caused by Clostridium difficile , a priority...
29.03.2018
2017: ambitions confirmed, milestones reached, and financial results in line with the development strategy
Acceleration of the Antibiotics program: €14.6m of funding by Bpifrance (including € 10.4m for the DEINOVE Group) and structuring of the...
28.09.2017
2017 half-year consolidated results: stability of net loss major progress on R&D programs in health, nutrition and cosmetics
Cash position: +€6.6m at June 30, 2017 compared to +€9.3m at December 31, 2016. Half-year net loss of DEINOVE Group (composed of DEINOVE...
16.05.2017
Shareholders’ meeting of May 16, 2017: Hervé BRAILLY joins the Board of Directors
Hervé Brailly, co-founder and executive of Innate Pharma SA [IPH], one of the world's leading immuno-oncology specialists and one of the...
30.03.2017
2016 annual results: Strategic focus on track – promising results in the fields of health, nutrition and cosmetics
Cash position of €9.3 million, and net loss down 1% to €6.3 million Strategic focus on high value-added applications in the healthcare,...
23.01.2017
DEINOVE strengthens its Board in line with its strategic focus
Four directors of international standing and experts in pharmaceutical industry and antibiotics join the Board of Directors: Bernard Fanget...